Preclinical Immune Monitoring Assay Platform for Cancer Vaccines

Q: What is the primary advantage of your 'Immune Risk Assessment' model?

Our model quantifies the ratio of effectors to suppressors (e.g., CD8+/Treg), allowing us to predict if the vaccine-induced response will be neutralized by the TME, providing a much more accurate forecast of therapeutic success than tumor volume alone.

Q: Can you perform immune monitoring on small-volume preclinical samples?

Yes, we have optimized high-sensitivity protocols for serial collection of peripheral blood and fine-needle biopsies, using platforms like FluoroSpot designed to extract maximum information from minimal sample sizes.

Q: Do you offer help with the selection of checkpoints to monitor?

Absolutely. Our scientists perform bioinformatic screening and multiplex profiling to identify the most relevant checkpoints (e.g., PD-1, TIGIT) upregulated in your specific tumor model for targeted monitoring.

Q: What is the typical turnaround time for a comprehensive monitoring report?

Preliminary flow and ELISpot data are provided within 7-10 business days, with full integrative reports including spatial IHC and PD analysis typically delivered within 3-4 weeks.

Decoding the balance between activation and regulation for precision immunotherapy. Creative Biolabs provides a comprehensive preclinical immune monitoring platform designed to evaluate the dynamic immune landscape induced by cancer vaccines.

Our platform utilizes advanced Immune Risk Assessment models to track effector CD8+ T-cell responses against immunosuppressive barriers (Tregs/MDSCs), ensuring that your vaccine candidate not only primes the system but also effectively modulates the tumor microenvironment (TME).

Discuss Your Monitoring Strategy

Why Immune Monitoring? The Key to Predictive Efficacy

Traditional endpoints like tumor volume often fail to capture the underlying mechanisms of vaccine success or failure. Our platform focuses on high-resolution "immune fingerprinting" to provide actionable insights:

▶ Quantifying Effector Potency: Using IFN-γ ELISpot and intracellular cytokine staining (ICS) to measure the magnitude and quality of vaccine-induced T-cell responses.
▶ Mapping Immunosuppressive Barriers: Identifying the enrichment of Tregs, MDSCs, and inhibitory checkpoints that limit vaccine efficacy in "cold" or high-risk tumors.
▶ Guiding Combination Therapy: Providing the "Immune Risk Assessment" data needed to rationally design synergy with ICIs or Treg-depleting agents.

Specialized Preclinical Monitoring Solutions

We offer a fully integrated suite of assays to dissect the complex immune responses in animal models:

High-Parameter Flow Cytometry

Detailed phenotyping of lymphoid and myeloid subsets. We track activation markers (CD69/HLA-DR) and exhaustion profiles (PD-1/LAG-3) across diverse tissues.

ELISpot & FluoroSpot Assays

Quantitative detection of single (IFN-γ) or multiple (IFN-γ/IL-2/TNF-α) cytokine-secreting cells at the single-cell level for unmatched sensitivity.

Spatial Immunohistochemistry (IHC)

Visualizing the spatial architecture of the TME. We map the infiltration density of TILs relative to tumor nests and the distribution of suppressive FOXP3+ Tregs.

Cytokine Profiling

Multiplex analysis of serum or TME-derived cytokines and chemokines (up to 40 analytes) to evaluate the overall inflammatory or suppressive "tone."

Featured Preclinical Focus Areas

Targeted immune monitoring for the most challenging oncological landscapes:

High-Risk Neuroblastoma

Evaluating the delicate balance between activatory T-cell expansion and regulatory Treg suppression in pediatric high-risk neuroblastoma models.

Explore Pediatric Models →

Suppressive TME Characterization

Identifying MDSC enrichment and TGF-β signatures that contribute to "immune risk," guiding the selection of synergistic ICI therapies.

View TME Solutions →

Vaccine PK/PD Correlation

Correlating longitudinal immune kinetics (e.g., peak effector response) with tumor growth inhibition (TGI) to optimize dosing schedules.

Learn About PD Mapping →

Neoantigen Specificity Validation

Utilizing peptide-MHC tetramers to quantify the absolute frequency of neoantigen-specific T-cell clones induced by personalized vaccines.

Get Specificity Data →

Agile Preclinical Immune Monitoring Workflow

Our systematic pipeline ensures the transformation of complex immune data into actionable development insights:

Step 1: Baseline Profiling & Panel Design

Activities: Defining the pre-vaccination "immune baseline" in tumor-bearing models. Designing customized flow cytometry and IHC panels targeting project-specific markers (e.g., TIGIT, VISTA, or CD103+ DC subsets).

Outcome: A finalized monitoring plan optimized for the vaccine's mechanism of action.

Step 2: Longitudinal Sample Collection & Processing

Activities: Serial collection of peripheral blood, spleen, and draining lymph nodes. Specialized processing of tumor-infiltrating lymphocytes (TILs) using gentle enzymatic digestion to preserve membrane markers and viability.

Outcome: High-quality single-cell suspensions ready for multi-parameter analysis.

Step 3: Effector Response Quantification

Activities: Assessment of vaccine-induced T-cell magnitude via ELISpot and functionality via polyfunctional cytokine profiling. Quantification of antigen-specific clones using tetramer staining or TCR repertoire sequencing.

Outcome: High-resolution data on the "Activatory" arm of the immune system.

Step 4: Regulatory Barrier & TME Assessment

Activities: Quantification of suppressive populations (Tregs, M2-Macs) and spatial analysis of the "Immune Excluded" architectures. Evaluating the relief of exhaustion markers following vaccine administration.

Outcome: Identification of dominant immune resistance mechanisms.

Step 5: Integrated Efficacy & Risk Report

Activities: Applying the "Immune Risk Assessment" model to correlate cellular dynamics with antitumor efficacy. Providing data-driven recommendations for combination therapy or dosing optimization.

Outcome: A comprehensive preclinical monitoring dossier for IND-enabling studies.

Discuss Your Monitoring Timeline

Core Immune Monitoring Platforms

Our solutions are powered by industry-leading systems tailored for the dissection of complex immune responses:

Immuno-Balance Analysis Hub: A specialized platform designed to quantify the "activatory/regulatory ratio." This platform integrates data from flow cytometry and ELISpot to determine whether a vaccine has successfully shifted the immune balance toward a pro-inflammatory state.

Automated ratio calculation for CD8+/Treg populations
Validated panels for high-risk pediatric and adult tumor models
High-throughput data visualization suites

Exhaustion-Mapper Suite: Advanced flow cytometry platform focusing on the T-cell exhaustion continuum. It tracks the expression of multiple inhibitory receptors (PD-1, CTLA-4, TIM-3) to predict the necessity of ICI combination.

18-parameter deep phenotyping
Kinetic analysis of exhaustion marker development
Single-cell polyfunctionality assessment

TME-Spatial Insight Center: A modular platform combining multiplex IF and spatial transcriptomics to visualize the "geography of immunity." This platform helps determine if vaccine-induced T cells are entering the tumor core or are trapped in the stroma.

In-situ visualization of up to 7 markers per slide
Quantification of "Immune Desert" vs. "Immune Infiltrated" zones
Correlation with local cytokine signatures

Immuno-Balance

Exhaustion-Mapper

TME-Spatial Insight

Scientific Insight: Monitoring High-Risk Neuroblastoma

Balancing Activation and Regulation (Szanto et al., 2021)

Discovery: Research published in Cancers underscores the critical importance of monitoring both the "gas" and the "brakes" of the immune system during cancer therapy. The study utilized integrated monitoring to reveal how activatory and regulatory responses dictate outcomes in high-risk neuroblastoma.

Research Highlights:

Mechanism: Combined ELISpot, flow cytometry, and IHC to assess the balance between CD8+ effector T cells and FOXP3+ Tregs.
Industry Application: Provided a robust "Immune Risk Assessment" model that allows researchers to identify immunosuppressive niches (e.g., MDSC enrichment).
Therapeutic Guidance: Demonstrates that overcoming the low efficacy of single therapies requires monitoring-guided combination strategies (e.g., vaccine + ICIs).

NK-cell activation-associated protein expression during IL-2 immunotherapy.

Fig.1 Upregulation of NK-cell activation-associated proteins during IL-2-containing immunotherapy.^1,2

Frequently Asked Questions

Q: What is the primary advantage of your 'Immune Risk Assessment' model?

A: Unlike standard assays that only count T cells, our model quantifies the ratio of effectors to suppressors (e.g., CD8+/Treg). This allows us to predict whether the vaccine-induced response will be neutralized by the TME, providing a much more accurate forecast of therapeutic success than tumor volume alone.

Q: Can you perform immune monitoring on small-volume preclinical samples?

A: Yes. We have optimized high-sensitivity protocols for processing small animal samples, including tail-vein blood and fine-needle tumor biopsies. Our FluoroSpot and 18-parameter flow platforms are designed to extract maximum biological information from minimal sample sizes.

Q: How do you differentiate between vaccine-induced T cells and endogenous ones?

A: We utilize peptide-MHC tetramer staining and ELISpot with specific vaccine-antigen peptides. By comparing these to responses against irrelevant antigens or baseline levels, we can precisely quantify the frequency and magnitude of the de novo immune response triggered by the vaccine.

Q: Do you offer help with the selection of checkpoints to monitor?

A: Absolutely. Our scientists can perform preliminary bioinformatic screening to identify the most relevant checkpoints (e.g., PD-1, TIGIT, LAG-3) upregulated in your specific tumor model, ensuring your monitoring panel is highly targeted.

Q: What is the typical turnaround time for a comprehensive monitoring report?

A: For standard preclinical studies, we typically provide preliminary data (flow/ELISpot) within 7-10 business days of sample receipt. A full integrative report, including IHC and PD correlation analysis, is usually delivered within 3-4 weeks.

Related Resources

References:
1. Szanto, Celina L., et al. "Immune monitoring during therapy reveals activitory and regulatory immune responses in high-risk neuroblastoma." Cancers 13.9 (2021): 2096.
2. Distributed under Open Access License CC BY 4.0, without modification.